Reporters Talk Through FDA Sunscreen Move and Closure of Rural Dialysis Clinics
KFF Health News journalists made the rounds on national media last week to discuss topical stories. Here’s a collection of their appearances.
The independent source for health policy research, polling, and news.
1 - 20 of 468 Results
KFF Health News journalists made the rounds on national media last week to discuss topical stories. Here’s a collection of their appearances.
As a federal court mulls a case that could result in significant restrictions on a pill used in most abortions, providers say they have alternatives to preserve access even in states with bans in place.
Four years after the Volunteer State enacted the nation’s first law allowing drugstores to sell ivermectin without patient-specific prescriptions, dozens of pharmacies dispense the drug in highly concentrated pills — many with the help of one anti-vaccine physician.
The Trump administration has pursued an extensive pro-tobacco agenda as the president and his political movement have been buoyed by a flood of tobacco industry money, federal records show.
The FDA has approved the sunscreen chemical bemotrizinol, a UV light filter that has been available in Europe, Asia, and Australia for more than 20 years. Health advocates and skin care industry groups alike are hopeful it can restore faith in sunscreen.
Infectious disease specialists say the viruses are unlikely to become pandemics, but some are still raising concerns about the federal health response and what it portends should a pandemic similar to or worse than covid occur.
Many telehealth companies have emerged in recent years offering easy access to GLP-1 weight loss drugs as demand has exploded. Meanwhile, researchers and doctors are concerned that some of these online companies aren't properly screening or monitoring patients. “It gives a black eye to telemedicine,” one researcher said.
Podcast host Julie Rovner chats with Sen. Tammy Baldwin, a top Democrat on health issues, about President Donald Trump’s stewardship of federal spending and the effectiveness of the 988 Suicide & Crisis Lifeline.
A third of patients in a clinical trial had tumors shrink while taking a genetically engineered treatment known as RP1.
For all of President Donald Trump’s showmanship, the share of Americans his policies will likely help remains slim, even if some patients do come out ahead.
KFF Health News journalists made the rounds on national and local media recently to discuss topical stories. Here’s a collection of their appearances.
The Trump administration faces the challenge of naming a new director of the Centers for Disease Control and Prevention who can both satisfy the Make America Healthy Again movement and get confirmed by the Senate. Meanwhile, a new Senate bill to rescind the approval of the abortion pill mifepristone is again elevating the abortion debate, which some Republicans would prefer to stay on the back burner until after the midterms. Shefali Luthra of The 19th, Lizzy Lawrence of Stat, and Rachel Cohrs Zhang of Bloomberg News join KFF Health News’ Julie Rovner to discuss the news. Also this week, Rovner interviews Georgetown University Law Center’s Katie Keith about the state of the Affordable Care Act on its 16th anniversary.
Some researchers and recovery advocates see the NET device as the latest in a series of products pitched as the solution to the addiction crisis that have been overhyped to capitalize on money from the opioid settlements.
HHS Secretary Robert F. Kennedy Jr. had another tough week. In addition to Kennedy having rotator cuff surgery, the nomination of his ally to become surgeon general is teetering, the controversial head of the FDA's vaccine center is resigning next month, and a new survey shows Americans trust government health officials less than they do former Biden official Anthony Fauci. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, and Shefali Luthra of The 19th join KFF Health News’ Julie Rovner to discuss these stories and more.
The twists and turns continue at the nation’s health agency, where this week’s announcements included notice that the FDA will review Moderna’s new flu vaccine after all and that a handful of top agency officials are getting new jobs. Those developments and others can be traced to a White House looking to shake things up before the midterms — and win over voters on health care. Tami Luhby of CNN, Shefali Luthra of The 19th, and Lauren Weber of The Washington Post join KFF Health News’ Mary Agnes Carey to discuss these stories and more.
It’s been a busy week at the FDA, with a political appointee overruling agency scientists to reject an application for a new flu vaccine. Meanwhile, anti-abortion Republicans on Capitol Hill complain the agency is dragging its feet on reviewing the abortion pill mifepristone. Jackie Fortiér of KFF Health News, Lizzy Lawrence of Stat, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss these stories and more.
At a January event organized by allies of health secretary Robert F. Kennedy Jr., National Cancer Institute Director Anthony Letai said results may be released “in a few months.” Ivermectin, used to deworm horses and other animals, has become a symbol of resistance against the medical establishment among supporters of Kennedy’s “Make America Healthy Again” agenda and many conservatives.
Get our weekly newsletter, The Week in Brief, featuring a roundup of our original coverage, Fridays at 2 p.m. ET.
With abortions still on the rise nationwide despite widespread bans, curtailing the use of pregnancy-terminating medication is a top priority for abortion opponents — and they’re frustrated that the Trump administration isn’t doing more to limit its use.
With lawmakers still mired over renewing enhanced tax credits for Affordable Care Act plans, much of Washington has turned to culture war issues. Meanwhile, “confusion” remains the watchword at HHS as personnel and funding decisions continue to be made and unmade with little notice. Anna Edney of Bloomberg News, Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico Magazine, and Alice Miranda Ollstein of Politico join KFF Health News’ Julie Rovner to discuss those stories and more. Also this week, Rovner interviews KFF Health News’ Elisabeth Rosenthal, who wrote the latest “Bill of the Month” report.
© 2026 KFF